Literature DB >> 1420669

Antibiotic-associated diarrhea.

J G Bartlett1.   

Abstract

Diarrhea is clearly one of the most common side effects encountered with antimicrobial treatment. Virtually all drugs with an antibacterial spectrum of activity have been implicated, although there are definite differences in associated incidence rates that appear to depend on spectrum of activity and pharmacokinetic properties. Most cases of antibiotic-associated diarrhea can be classified in two categories: cases in which Clostridium difficile is implicated and cases in which no putative agent or recognized pathophysiological mechanism is clearly established. This review is intended to provide management guidelines for patients with diarrhea that occurs in association with antibacterial agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1420669     DOI: 10.1093/clind/15.4.573

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  81 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  Patterns of sequence conservation in the S-Layer proteins and related sequences in Clostridium difficile.

Authors:  Emanuela Calabi; Neil Fairweather
Journal:  J Bacteriol       Date:  2002-07       Impact factor: 3.490

3.  Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary.

Authors:  Gabriella Terhes; Edit Urbán; József Sóki; Kanjo Abdul Hamid; Elisabeth Nagy
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

4.  Clostridium difficile colitis in children with cystic fibrosis.

Authors:  Sunny Zaheed Hussain; Cathy Chu; David P Greenberg; David Orenstein; Seema Khan
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

Review 5.  Molecular techniques for diagnosis of Clostridium difficile infection: systematic review and meta-analysis.

Authors:  John C O'Horo; Amy Jones; Matthew Sternke; Christopher Harper; Nasia Safdar
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

Review 6.  From structure to function: the ecology of host-associated microbial communities.

Authors:  Courtney J Robinson; Brendan J M Bohannan; Vincent B Young
Journal:  Microbiol Mol Biol Rev       Date:  2010-09       Impact factor: 11.056

7.  Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.

Authors:  Michael John Aldape; Dustin Delaney Heeney; Amy Evelyn Bryant; Dennis Leroy Stevens
Journal:  J Antimicrob Chemother       Date:  2014-08-23       Impact factor: 5.790

8.  In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.

Authors:  Sydney M Finegold; Denise Molitoris; Marja-Liisa Vaisanen; Yuli Song; Chengxu Liu; Mauricio Bolaños
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

9.  Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Authors:  Kim L Credito; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

10.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.